Elicera Therapeutics Investor Relations Material

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The company focuses on developing next-generation cell and gene therapies aimed at treating cancer through immune-based approaches. Elicera's pipeline includes four main drug candidates, two of which are in the field of oncolytic viruses and two in CAR T-cell therapies. Their proprietary iTANK (ImmunoTherapies Activated with Nap for efficient Killing) platform is designed to enhance the efficacy of these therapies. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Nasdaq Stockholm.